Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Sponsor
Incyte Corporation
Study ID
NCT06465433
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Tafasitamab — DRUG
    Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.

Study Details

This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..

Key Dates

Start date
Nov 8, 2022
Status verified
Dec 2025
Primary completion
Aug 29, 2027
Completion
Aug 29, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tafasitamab Dose
    Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.

Primary Outcome Measure

Number of participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: up to approximately 2 years ]

Central Contacts

Related Studies